Country/region | Current smoker (%) | Mean (SD) diabetes duration (years) | Screened for diabetes-related complications (%)* | With microvascular complications (%)* | With macrovascular complications (%)* | With HbA1c<7% (%) | Familial history of T2DM (%) |
---|---|---|---|---|---|---|---|
Eurasia (n=1834) | 9.8 | 8.7 (7.1) | 99 | 87 | 47 | 21 | 37.9 |
Georgia (n=152) | 13.2 | 10.7 (8.6) | 99 | 91 | 74 | 4 | 42.8 |
Kazakhstan (n=413) | 11.1 | 8.1 (7.3) | 100 | 89 | 40 | 21 | 27.4 |
Russia (n=540) | 9.3 | 9.5 (7.4) | 99 | 81 | 42 | 29 | 40.9 |
Ukraine (n=353) | 8.5 | 9.2 (6.3) | 97 | 89 | 53 | 15 | 41.8 |
Uzbekistan (n=376) | 8.8 | 6.8 (5.7) | 100 | 89 | 47 | 23 | 39.6 |
Africa (n=2220)† | 8.1 | 8.6 (7.2) | 93 | 41 | 14 | 31 | 52.3 |
Algeria (n=514) | 4.5 | 8.8 (7.1) | 97 | 41 | 15 | 44 | 51.3 |
Cameroon (n=524) | 2.7 | 6.6 (6.9) | 90 | 48 | 6 | 28 | 44.5 |
Egypt (n=371) | 17.8 | 9.4 (7.7) | 93 | 47 | 20 | 22 | 58.2 |
Morocco (n=498) | 5.0 | 9.0 (7.0) | 91 | 30 | 15 | 27 | 53.7 |
Tunisia (n=313) | 16.9 | 10.0 (6.7) | 98 | 39 | 15 | 23 | 58.5 |
Middle East (n=2065) | 22.9 | 8.3 (7.2) | 96 | 35 | 15 | 37 | 59.5 |
Jordan (n=296) | 28.7 | 6.6 (5.9) | 93 | 30 | 15 | 34 | 55.4 |
KSA (n=199) | 18.6 | 10.2 (8.2) | 94 | 48 | 19 | 31 | 63.3 |
Lebanon (n=1059) | 28.0 | 8.1 (7.2) | 95 | 35 | 17 | 36 | 60.4 |
UAE (n=511) | 10.6 | 9.1 (7.0) | 99 | 30 | 10 | 42 | 58.3 |
South Asia (n=1195) | 8.8 | 9.0 (6.7) | 91 | 41 | 14 | 25 | 43.2 |
India (n=994) | 7.7 | 9.1 (6.5) | 91 | 37 | 11 | 26 | 43.0 |
Pakistan (n=201) | 14.4 | 8.2 (7.2) | 92 | 62 | 27 | 22 | 44.6 |
Turkey (n=842) | 14.5 | 8.7 (6.8) | 94 | 42 | 20 | 28 | 55.5 |
*Missing data are considered for percentage calculations.
†Owing to the small sample size (N=50), Senegal was not included in Africa results in this table.
HbA1c, glycated hemoglobin; KSA, Kingdom of Saudi Arabia; T2DM, type 2 diabetes mellitus; UAE,United Arab Emirates.